drugset / Trial / NCT01225549

The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

NCT01225549

Phase 2 Completed 27 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.

Timeline

Start
2010-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5423 Other / unclassified 75 ug Inhaled
Subject AZD5423 Other / unclassified 300 ug Inhaled
Comparator Budesonide Small molecule 200 ug Inhaled

Indications